Journal
COMPUTERS IN BIOLOGY AND MEDICINE
Volume 137, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.compbiomed.2021.104826
Keywords
SARS-CoV-2-RdRp; Gastric cancer; Kinase inhibitors; Molecular docking; MD simulation
Categories
Funding
- Department of Science and Technology as Ramanujan fellowship [SB/S2/RIN-132/20/5, EMR/2017/001637]
- CSIR, India [09/1022(0035)/2017-EMR-I]
- UGC-New Delhi
Ask authors/readers for more resources
The global pandemic of COVID-19 caused by SARS-CoV-2 poses a challenge for health management in gastric cancer patients. FDA-approved drugs for gastric cancer have high binding energies against SARS-CoV-2, potentially playing a key role in treatment for COVID-19 patients with gastric cancer as comorbidity. Kinases may serve as key therapeutic targets in the treatment of COVID-19.
Corona Virus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has become a global pandemic. Additionally, the SARS-CoV-2 infection in the patients of Gastric Cancer (GC; the third leading cause of death in the world) pose a great challenge for the health management of the patients. Since there have been uncertainties to develop a new drug against COVID-19, there is an urgent need for repurposing drugs that can target key proteins of both SARS-CoV-2 and GC. The SARS-CoV-2-RdRp protein contains the NiRAN domain, which is known to have kinase-like folds. A docking study of the FDA approved drugs against GC was performed using AutoDock 4.2 and Glide Schrodinger suite 2019 against SARS-CoV-2RdRp protein. MMGBSA and MD simulation studies were performed to investigate the binding and stability of the inhibitors with the target protein. In this study, we have found 12 kinase inhibitors with high binding energies namely Baricitinib, Brepocitinib, Decernotinib, Fasudil, Filgotinib, GSK2606414, Peficitinib, Ruxolitinib, Tofacitinib, Upadacitinib, Pamapimod and Ibrutinib. These FDA approved drugs against GC can play a key role in the treatment of COVID-19 patients along with GC as comorbidity. We also hypothesize that JAK, ITK, Rhoassociated kinases, FGFR2, FYN, PERK, TYK2, p38-MAPK and SYK kinases can be considered as key therapeutic targets in COVID-19 treatment. Taken altogether, we have proposed the SARS-CoV-2-RdRp as a potential therapeutic target through in-silico studies. However, further in-vitro and in-vivo studies are required for the validation of the proposed targets and drugs for the treatment of COVID-19 patients already suffering from GC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available